Foundayo UK Approval Status: What Is Officially Confirmed?

Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 medicine. Since its UK authorisation, there has been a lot of interest in what the approval actually means.

This page sets out what has actually been confirmed by the regulator, what that confirmation means in practice, and which claims circulating alongside it do not hold up.

Key things to know

• The MHRA authorised orforglipron, sold as Foundayo, on 10 August 2026.
• The MHRA said this made the UK the first country in Europe to approve this GLP-1 tablet.
• It is licensed for weight management and, separately, for type 2 diabetes.
• The weight management licence applies alongside a reduced-calorie diet and increased physical activity.
• The MHRA has not described the decision as expedited.
• MHRA authorisation does not mean every pharmacy will have stock, and Foundayo remains a prescription-only medicine.

Is Foundayo by Eli Lilly approved in the UK?

Yes. The MHRA authorised orforglipron under the brand name Foundayo on 10 August 2026, and stated that the decision made the UK the first country in Europe to approve this GLP-1 tablet.

The medicine had already been approved in the United States earlier in 2026, under the same brand name.

What the MHRA authorised for chronic weight management

The licence covers two separate uses.

Weight management. Weight loss and weight maintenance in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related health condition, alongside a reduced-calorie diet and increased physical activity.

Type 2 diabetes. Improving blood glucose control in adults with insufficiently controlled type 2 diabetes.

Two details in that wording matter and are usually skipped in the coverage.

The diet and activity requirement sits inside the licensed indication itself. The medicine is authorised as an addition to those changes, not as an alternative to them.

And the weight management licence sets specific BMI criteria. It is not authorised for general or cosmetic weight loss, and a legitimate prescriber will assess you against those criteria.

When was Foundayo approved?

This is why the MHRA described the UK as the first country in Europe to approve orforglipron.

Was Foundayo given expedited approval?

This claim appears widely, and it is worth being precise.

The MHRA's announcement describes the authorisation and notes that the UK was first in Europe. It does not describe the decision as expedited, fast-tracked or accelerated, and we have not seen the regulator characterise it that way.

Being first in Europe is not the same thing. Regulators work to their own timetables, and in the UK the MHRA regulates all medicines and medical devices. Submissions do not arrive in every country at the same moment. One country approving before another tells you about sequencing, not about the speed or thoroughness of the assessment.

This distinction matters because "expedited" implies shortcuts to people reading quickly. If you see that claim attached to any medicine, it is worth checking whether the regulator said it or whether someone inferred it from the timing.

What approval does not mean

This is where most of the confusion sits.

It does not mean the medicine is in stock. MHRA authorisation means the medicine has been authorised for supply in the UK, but it does not mean every pharmacy will have it in stock. Availability depends on supply and individual providers.Supply of a newly licensed medicine takes time to reach pharmacies, and the position changes. Check with a registered pharmacy rather than assuming.

It does not mean you can buy it without a prescription. Foundayo remains prescription-only. If a website claims to supply it without the required clinical assessment and prescription, treat that as a warning sign and check that the pharmacy is properly regulated.

It does not mean it suits you. A licence describes the population a medicine has been authorised for. Whether it is appropriate for a particular person depends on their medical history, other conditions and other medicines. Treatment suitability depends on an individual clinical assessment, and your prescriber will determine the appropriate treatment.

It does not rank it against other treatments. Approval also does not mean Foundayo is better or worse than other weight-management medicines. The UK authorisation confirms that the regulator considered its benefits and risks acceptable for the approved uses. It is not a ranking of treatments.

It does not settle the long-term picture. Newly authorised medicines have less real-world use behind them than established ones. The MHRA has said it will keep the safety and effectiveness of this medicine under close review, which is standard for a new authorisation. Wider NHS availability depends on guidance from the National Institute for Health and Care Excellence.

What has not been confirmed

Being clear about the gaps is as useful as listing the facts.

• How it compares with other weight management medicines, since no head-to-head trials have been published
• Long-term outcomes beyond the periods studied in trials
• Real-world tolerability at scale, which only accumulates with use

For claims about comparisons, long-term outcomes or real-world experience, check whether the information comes from the regulator, the official product information, published clinical research or another clearly identified source.

Where the official information is

The Summary of Product Characteristics and the patient information leaflet are the authoritative sources for licensed doses, the full list of side effects, contraindications and how the medicine should be used. They also cover practical administration details, including that orforglipron is taken once daily without food or water restrictions and that Foundayo can be taken with or without food because of its stability in stomach acid. The MHRA publishes both on its products website.

For licensed doses, contraindications, warnings and administration instructions, the current UK product information should take precedence over summaries on third-party websites.

Suspected side effects can be reported through the Yellow Card scheme, which the MHRA uses to monitor medicines in real use, for example, the product information lists common side effects such as nausea and abdominal pain. Reports from patients count, not only those from healthcare professionals.

Reading the weight loss coverage carefully

New weight management medicines attract more claims than most, and the gap between what a regulator has confirmed and what is said about it can be wide.

The reliable test is simple. Check what the regulator actually published, check the official product information for anything clinical, and treat confident claims about comparisons, availability or speed of approval with caution until you can trace them to a source.

Medical Disclaimer

This article is for general information only. It is not medical advice and it does not replace the Summary of Product Characteristics or patient information leaflet, or an individual assessment by an appropriately qualified healthcare professional.

Foundayo is a prescription-only medicine. It should only be used under the supervision of an appropriately qualified prescriber, following a clinical assessment that considers your medical history, current medicines and other conditions. Treatment suitability depends on an individual clinical assessment, and results vary between individuals.

Do not obtain prescription medicines outside the regulated system. Suspected side effects can be reported through the Yellow Card scheme, which the MHRA uses to monitor the safety of medicines.